Cardiovascular outcomes with ertugliflozin in type 2 diabetes

New England Journal of Medicine

Volumn 383, Issue 15, 2020, Pages 1425-1435

  Cannon, C P ^a   Pratley, R ^a   Dagogo Jack, S ^a   Mancuso, J ^a   Huyck, S ^a   Masiukiewicz, U ^a   Charbonnel, B ^a   Frederich, R ^a   Gallo, S ^a   Cosentino, F ^a   Shih, W J ^a   Gantz, I ^a   Terra, S G ^a   Cherney, D Z I ^a   McGuire, D K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ERTUGLIFLOZIN; PLACEBO; FUSED HETEROCYCLIC RINGS;

ACUTE KIDNEY FAILURE; ADULT; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DEATH; DIABETIC KETOACIDOSIS; DOUBLE BLIND PROCEDURE; FEMALE; FRACTURE; FUNGAL GENITAL INFECTION; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; HYPOVOLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; URINARY TRACT INFECTION; ADMINISTRATION AND DOSAGE; ADVERSE EVENT; AGED; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHY; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL;

AGED; ATHEROSCLEROSIS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85092567433     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa2004967     Document Type: Article

References (17)

1. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017;376:1407-18.
2. Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018;20:2000-3.
3. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016;12:73-81.
4. Thomas MC. Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev 2016;12:249-55.
5. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-86.
6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
7. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
8. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57.
9. European Medicines Agency. Steglatro (ertugliflozin): summary of product characteristics. Hoddesdon, United Kingdom: Merck Sharp & Dohme, 2018 (https://www.ema.europa.eu/en/documents/product -information/steglatro-epar-product -information_en.pdf).
10. Food and Drug Administration. Steglatro (ertugliflozin): prescribing information. Whitehouse Station, NJ: Merck Sharp & Dohme, 2017 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/ 209803s000lbl.pdf).
11. Food and Drug Administration. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-5 (https://www.govinfo.gov/content/pkg/ FR-2008-12-19/pdf/E8-30086.pdf).
12. Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 2018;206:11-23.
13. Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. Stat Biopharm Res 2013;5:311-20.
14. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994;13:1341-52.
15. Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther 2017;11:2905-19.
16. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
17. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306.